Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1232P is a pseudogene derived from the U6 small nuclear RNA (snRNA) gene. U6 snRNA itself is a highly conserved, short non-coding RNA critical for mRNA splicing via the spliceosome, but pseudogene copies such as RNU6-1232P lack protein-coding ability and are considered non-functional relics formed through retrotransposition mechanisms such as LINE-1 (L1) activity. These pseudogenes are widespread in the human genome and serve as markers of retrotransposition dynamics, but are not known to encode functional RNA or protein products, nor do they serve as receptors, enzymes, or other therapeutically relevant molecular targets. Key notes: - This entry describes a processed pseudogene of U6 snRNA, not an active or functional gene or therapeutic target, so it is not suitable for drug targeting, biomarker development, or disease association studies. - If the query presupposed a molecular target, this is incorrect, as RNU6-1232P is a pseudogene and not used in clinical, pharmacological, or research targeting contexts. - No canonical functional protein or active RNA product is encoded, so all target-relevant fields are null or not applicable. - The most scientifically accurate name is "RNA, U6 small nuclear 1232, pseudogene" with abbreviation "RNU6-1232P". If more information on the functional U6 snRNA (not pseudogene) is needed, it is involved in the spliceosome and catalyzes the excision of introns from pre-mRNA in the nucleus, but the pseudogene version RNU6-1232P is not active.
None (not a therapeutic target)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1232, pseudogene (RNU6-1232P).